=

P&G is in a ‘much better place’ to withstand the next recession, CEO David Taylor says

“We don’t see consumers stopping laundry or shampooing or conditioning or feminine protection during a recession,” said P&G CEO David Taylor. P&G’s brands include Tide, Pantene and Tampax.

Under Armour’s Kevin Plank says he and new CEO Patrik Frisk will ‘divide and conquer’

Kevin Plank and Patrik Frisk will “divide and conquer” their responsibilities in leading Under Armour, the duo told CNBC Tuesday morning, on the heels of the company announcing Plank will step down as CEO on Jan. 1.

5 tips on how to woo a deep-pocketed angel investor to fund your big idea

Angel investors and angel networks are proliferating across America. Here are five ways to woo one that aligns with your business goals.

Bezos unveils Blue Origin will work on lunar lander with Lockheed Martin, Northrop Grumman & Draper

Bezos spoke at the 70th International Astronautical Congress on Tuesday.

2022 Winter Olympics should not be held in China, GOP Sen. Rick Scott says

“Until you become a legitimate country that is going to respect human rights and respect things you agree to, we’re going to quit doing business with you

Not well? Your credit card debt could be making you sick

Americans are taking on ever-increasing amounts of debt and it’s harming their overall health and relationships, according to researchers.

NBA star Beal, who just signed $72 million extension, says ‘all the jewelry, all the cars’ get old

Beal’s $72 million extension with the Washington Wizards adds two years to his five-year, $127 million contract he signed in 2016.

Lockheed Martin profit up but forecasts lower cash flow in 2020; shares slip

Lockheed Martin raised its forecast for 2019 earnings as it reported a 9.2% rise in quarterly profit on Tuesday, helped by increased sales in its aeronautics business, which makes F-35 fighter jets.

Biogen to seek US approval for Alzheimer’s drug, sending shares soaring 40%

Biogen is planning to file for U.S. regulatory approval for its Alzheimer’s treatment aducanumab after fresh analysis of its clinical trial showed promise, the drugmaker said.